Kura leaves some combo questions unanswered
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
Interview – Kura’s combo test nears
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
ASH 2023 movers – an unexpected comeback for MorphoSys
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
ASH 2023 – J&J makes menin a three-horse race
But JNJ-75276617 still has much to prove.
ASH 2023 preview – small-molecule duels
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.
The menin fault lines emerge
With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.
